Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx Inc (NASDAQ: ARDX) is a biopharmaceutical company pioneering first-in-class therapies for renal and gastrointestinal disorders. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Discover official press releases covering tenapanor developments, hyperphosphatemia research breakthroughs, and international collaboration updates with partners in Japan and China. Our curated collection includes financial results, manufacturing announcements, and expert analyses of ARDX's novel drug discovery platform.
Key content categories include FDA regulatory updates, phase 3 clinical trial results, partnership expansions, and financial performance reports. All materials maintain strict compliance with financial disclosure regulations while presenting complex medical information in accessible language.
Bookmark this page for real-time updates on ARDX's progress in developing treatments for chronic kidney disease and IBS-C. Regularly refreshed content ensures you stay informed about this innovative biotech leader's contributions to renal care and gastrointestinal health.
Ardelyx, Inc. (NASDAQ: ARDX) announced a conference call to discuss its first quarter financial results and provide a business update on May 3, 2023, at 4:30 p.m. ET. The call can be accessed by dialing (844) 481-2838 domestically or (412) 317-1858 internationally, with a live audio webcast available on the company’s website. Ardelyx is committed to developing first-in-class medicines for unmet medical needs, having achieved success with its approved product IBSRELA® (tenapanor). Additionally, the company is advancing XPHOZAH® for chronic kidney disease patients and has multiple collaborations in place with international partners for the commercialization of tenapanor. More details can be found on Ardelyx's website.
Ardelyx, Inc. (Nasdaq: ARDX) has announced the resubmission of a New Drug Application (NDA) for XPHOZAH (tenapanor) targeting serum phosphate control in adults with chronic kidney disease (CKD) on dialysis. This NDA supports over 1,200 patients' data from three successful Phase 3 trials and two Phase 4 trials, all meeting critical endpoints. Confirmation of the resubmission's completeness from the FDA is anticipated by mid-May. XPHOZAH functions as a phosphate absorption inhibitor, requiring a simple dosing regimen of one 30mg tablet twice daily. Hyperphosphatemia, affecting many CKD patients, underscores the drug's potential significance. Ardelyx continues to pursue innovative treatments for unmet medical needs.
FAQ
What is the current stock price of Ardelyx (ARDX)?
What is the market cap of Ardelyx (ARDX)?
